Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients.
The relationship between serum concentration of different components of the nerve growth factor/tumor necrosis factor (TNF) receptor family, including soluble APO-1/Fas (sAPO-1/Fas) and progression of HIV infection, was analyzed in a case-control study of individuals selected from a cohort of HIV-seropositive patients who were progressing or not progressing to AIDS while being treated with nucleoside analogs. HIV-seronegative healthy controls were also analyzed. The results showed that, despite close matching for immunologic (CD4 cell count, beta2-microglobulin concentration) and virologic (p24 antigen, detection of HIV syncytium-inducing phenotype, plasma HIV viremia) parameters, the baseline serum concentrations of TNF-beta and sAPO-1/Fas were statistically different between progressing and nonprogressing patients. In addition, serum concentrations of TNF-beta and sAPO-1/Fas showed the strongest independent predictive power for progression to AIDS in a multivariate conditional logistic regression model. Because TNF-beta and Fas were suggested to be mediators of antigen-induced cell death (AICD) in HIV infection and sAPO-1/Fas was hypothesized to protect lymphocyte against AICD, these data suggest an important pathogenetic role for AICD in the progression of HIV infection.
Medrano
F J
FJ
Viral Hepatitis and AIDS Study Group, Departamento de Medicina Interna, Hospital Universitario Virgen del Rocio, Seville, Spain.
Leal
M
M
Arienti
D
D
Rey
C
C
Zagliani
A
A
Torres
Y
Y
Sanchez-Quijano
A
A
Lissen
E
E
Clerici
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006679:HIV Seropositivity / Q000097:blood* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D006801:Humans; D008233:Lymphotoxin-alpha / Q000097:blood*; D008297:Male; D011237:Predictive Value of Tests; D012044:Regression Analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012995:Solubility; D015215:Zidovudine / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000032:analysis; D019014:fas Receptor / Q000097:blood*
D019380:Anti-HIV Agents; D015415:Biomarkers; D008233:Lymphotoxin-alpha; D018894:Reverse Transcriptase Inhibitors; D001613:beta 2-Microglobulin; D019014:fas Receptor; D015215:Zidovudine